Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06766071 · ClinicalTrials.gov registry record
IPGx PILOT Whole Genome Sequencing Extension Cohort
A clinical trial of Adverse Drug Reaction (ADR) and Polypharmacy Patients, sponsored by Texas A&M University.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT06766071: Recruiting study of Adverse Drug Reaction (ADR) and Polypharmacy Patients, sponsored by Texas A&M University.
NCT06766071 is a study of Adverse Drug Reaction (ADR) and Polypharmacy Patients that is actively recruiting participants, run by Texas A&M University. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06766071, a study of Adverse Drug Reaction (ADR) and Polypharmacy Patients, is actively recruiting participants, sponsored by Texas A&M University.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity/saturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice including Whole Genome Sequencing (WGS).
Primary Outcome
Patients will be referred to the Texas A\&M Interprofessional Pharmacogenomics Clinic (IPGx) by their primary care physicians to evaluate genotyping and ADR. Clinical staff will obtain a buccal swab to collect DNA for a pharmacogenomic evaluation pursuant to the sample collection kits from the CLIA lab, which will occur at the start of the study period. Blood chemistry will be taken from the EMR.
Conditions Studied
Study Locations (1)
Texas
- Texas A&M Family Care - Bryan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-01 |
| Est. Completion | 2026-01 |
What NCT06766071 shows while recruiting
NCT06766071 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 2 conditions, with Adverse Drug Reaction (ADR) appearing as the primary indexed condition, and to 0 interventions.
NCT06766071 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06766071 about?
NCT06766071 is a clinical study titled "IPGx PILOT Whole Genome Sequencing Extension Cohort". The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from th...
What is the current status of trial NCT06766071?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-01. Estimated completion is 2026-01.
What conditions does trial NCT06766071 study?
This clinical trial studies the following conditions: Adverse Drug Reaction (ADR), Polypharmacy Patients.
Who is sponsoring clinical trial NCT06766071?
This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06766071 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adverse Drug Reaction (ADR)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia